Pharmaceutical companies frequent action, weight-loss medicine break cocoon soon?

Source: Analysts of Xinkangjie 2014-09-22 have been waiting until pharmaceutical companies realize the huge potential of weight-loss drug market At present, a large number of companies, including Novo Nordisk and Takeda pharmaceutical, are actively paying for new weight-loss drugs At the same time, they are beginning to lay out the market, and weight-loss drugs are finally favored by pharmaceutical companies Last week, Novo Nordisk's weight-loss drug, liraglutide, saxenda, was backed by an FDA advisory committee and is being prepared to benefit "the best people" in the obesity field, MADS krogsgaard Thomsen, the company's chief scientific officer, told Bloomberg In addition to adding hundreds of R & D personnel, Novo Nordisk plans to work with universities and biotechnology companies to advise on the product "We're taking a holistic approach, as we've already done in the area of diabetes, to individualize medication for different patients," Thomsen said, citing the news media This is a boost to the confidence of weight-loss drug market, which will bring a good omen to other pharmaceutical companies attracted by weight-loss drug market For example, orexigen's newly approved weight-loss drugs: naltrexone hydrochloride and bupropion hydrochloride sustained-release tablets (contract) The drug's sales partner is Takeda pharmaceutical, which said it would put 900 people into the sales team for the weight-loss drug Novo Nordisk has prepared a strong sales force for saxenda If Novo Nordisk and Takeda go well, their new weight-loss drugs could trigger the multibillion dollar market analysts have long expected According to the Centers for Disease Control and prevention, more than one-third of American adults are obese, so there are many eligible patients Only two to 10 million patients are currently on diet pills, said Mark booth, chief business officer of orexigen, in a speech on Tuesday "The weight-loss drug market is a huge, fast-growing and potential market." But so far, pharmaceutical companies that have created a new generation of weight-loss drugs have had trouble gaining market share They are trying to persuade doctors to support diet pills, patients using them and taxpayers paying for them The second new weight-loss drug qsymia (slow-release preparation of phenylbutylamine and topiramate) approved by the FDA in September 2012 by vivus in California is in a sales dilemma, while its competitors, Lorcaserin and belviq, a new weight-loss drug from Irina pharmaceutical, are not performing as well, even though the sales partner of the product is Japanese Weicai In 2013, qsymia's sales were only $23.7 million, and belviq's net sales were just over $25 million Even so, analysts insist that the market for diet pills is about to change dramatically Matthew Andrews, an analyst at Wells Fargo, the best bank in the United States, said contract's sales will reach $634 million by 2020, and $1.2 billion if orexigen allows the drug to be used to treat diabetes He also predicted that by 2020, belviq's sales will reach 481 million dollars, and qsymia's sales will reach 396 million dollars Meanwhile, analysts from Bloomberg predicted saxenda's sales in 2017 will reach 429 million dollars In addition, Irina pharmaceutical is also developing its own development plan The company hopes to use belviq in combination with phentermine in the weight-loss drug Fen phen, so as to avoid the cardiovascular risk of Fen phen and stimulate sales.